Eric Low retweeted
Recommendations on diagnosis and initial treatment of patients with transplant-eligible high-risk multiple myeloma by the British Society of Haematology/UK Myeloma Society
buff.ly/4bw1Nok
@MyMKaiser
@DrSStern
@JennerMatthew
@UKMyelomaSoc
Eric Low retweeted
Delighted that the @BritSocHaem @UKMyelomaSoc Good Practice Paper on the treatment of high risk transplant-eligible myeloma is now published. Many thanks to @MyMKaiser for his great input. #mmsm
British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/…
Eric Low retweeted
Legendary @f2harrell is back at Consilium next week! Sign up here for the talk mailchi.mp/consilium-scienti… @PotardDechaine @EricLow71 @DrAmandaAdler @david_colquhoun @bogdienache @rarediseaseuk @ResurgeQuality @Richard_D_Riley @vandy_biostat @BabakWork
Eric Low retweeted
Great job @EMA_News @HAImedicines @TranspariMED @Meds_Alliance! Learn more here clinicaltrialsarena.com/news…
@nogracias_eu @RevuePrescrire @ISRCTN @METRICStanford @Marguerite_OR @Jhickmana @EricLow71 @GustavNilsonne @NDevito1
Eric Low retweeted
An exciting clinical research fellow in haematology post now open at UK National Amyloidosis Centre and UCLH amyloidosis/MGCS trials clinic - see #nhsjobs - 2-3 yrs with opportunities to do a PhD at UCL. @OSociety @BritSocHaem @EHA_Hematology @ASH_hematology @LinkedIn
Eric Low retweeted
Last chance for the #myeloma MRI quiz...
Another leap for quality-controlled WB-MRI for #myeloma . Huge opportunity for better imaging data in trials and their analysis. Amazing collaboration @CTRUmyeloma , thanks @JanssenEMEA @bmsnews for support. Interested in myeloma WB-MRI? see poll tweetorial below 👇 1/10
Eric Low retweeted
Join us for a special event to depict HTA methodology and celebrate the legacy of Dr.Eli Gajraj. Sign up here: mailchi.mp/consilium-scienti… @FrancoisMaignen @JacolineBouvy @SirAndrewDillon @dollendorf @OortwijnW @decide_health @NICESciAdvice @EUnetHTA @EricLow71 @pilarpinilladom
Eric Low retweeted
Many thanks, very kind. Deeply feel we should discuss the value of extended upfront risk molecular diagnostic tests more in #myeloma , not only price. We might find that they will help allocate other rare resources like imaging or MRD tests throughout treatment phases better.
Saving the best till last! Love @MyMKaiser talk at #ims23, Importance of co-occurrence of HRCA and relevance of GEP. We have the tools but we seem unable to translate and adopt. Also need to move from understanding biology to novel therapeutic strategies for truly HR MM!
Eric Low retweeted
Don't read? Well, here is the podcast: labiotech.eu/podcast/beyond-…
$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. @consiliumsci @Jhickmana
jamanetwork.com/journals/jam…
Eric Low retweeted
Join Consilium on June 16th for a talk from our brilliant AdBoard member Jack Scannell. Sign up here:
mailchi.mp/consilium-scienti… @Jhickmana @rkessler05 @RevuePrescrire @david_colquhoun @LSEHealthPolicy @HealthSenseUK @TranspariMED @HAImedicines @EricLow71 @Anticancerfund
Eric Low retweeted
$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. @consiliumsci @Jhickmana
jamanetwork.com/journals/jam…
Eric Low retweeted
If you missed a brilliant talk by @DrDavidHealy at Consilium, watch here youtu.be/Jby3xtEVm0g @riotscience_wlv @UKRIO @uaem @Jhickmana @eturnermd1 @EricLow71 @NaudetFlorian @susan_bewley @pash22 @HealthSenseUK @pssd_awareness @cheesyredrocket @PatrickChance @PatientStormDoc
Eric Low retweeted
Join to learn the results of the Consilium’s @MyelomaEurope funded project on QoL in multiple myeloma trials @Care4Access @KateEMor_ @drkevinknopf @MyMKaiser @FrancoisMaignen @EricLow71 @MyelomaUK @patvocates @Jhickmana @peterbachmd @AaronGoodman33 @VincentRK @pash22 @IMFmyeloma
Eric Low retweeted
If you missed an excellent talk on multi-modal cancer screening tests by @paulpharoah last week, watch here youtu.be/XSS1wk32bgw @ecancer @drkevinknopf @oncology_bg @EAEisenhauer @MyMKaiser @EricLow71 @EuropeanCancer @CRUK_Policy
Eric Low retweeted
If you missed an excellent live debate organised by @TranspariMED on how the UK trial transparency system can be implemented in other countries, watch here youtu.be/ubTcjbpfoU8 @cmarctaylor @Strech_Da @NDevito1 @HRA_Latest @matt_westmore @berlinnovation @EricLow71 @Jhickmana
Eric Low retweeted
Will be very interesting to see how this will work in practice - a fantastic, extremely scalable technology. And of course hoping #myeloma patients may be included as well! @BioNTech_Group @NCRI_partners #MMsm
ft.com/content/a0f74126-755d…
Eric Low retweeted
5 yrs into Optimum (MUK9) trial still going strong @MyMKaiser @CTRUmyeloma @MyelomaUK #UKMRA @UHNM_NHS kudos goes to myeloma experts brain collaboratively together.
Eric Low retweeted
OPTIMUM MUK9 @MyMKaiser: Extended 'kitchen sink' approach for ultra high risk #mmsm. Amazing effort & it's paying off. 30-month PFS is 77%. MRD(-) rates sustained from post-ASCT to subsequent time points. Even OS signal very encouraging. #ASH22
Eric Low retweeted
Please take a moment and vote for the Amyloidosis Forum.
The Amyloidosis Forum (an ARC partnership) has made it through to the final round of the @IamHeroX DataWorks! Challenge sponsored by @FASEBorg and @NIH. Now we need your help!
Vote now to help our #FederatedAnalytics platform win the final round:
herox.com/dataworks/round/24…
ALT Scientists in a research lab above a title reading, "FASEB DataWorks! Prize." The competition is powered by heroX